Sigma-Aldrich ‘strengthens position’ with purchase

Sigma-Aldrich has been "significantly strengthened" by new acquisitions, a spokesperson has said.

Dave Smoller, president of the research biotech business unit at the company, made the statement in reference to its takeover of Seppro technology and antibodies from GenWay Biotech.

Seppro’s technology relates to products that uncover protein biomarkers otherwise undetected.

It works by taking away proteins that exist in high quantities and is antibody-based.

GenWay Biotech’s 700-strong antibody library is derived from the embryos of chickens and involves the use of recombinant antigens.

It is the first time Sigma-Aldrich has possessed such products.

Mr Smoller stated: "Our goal, through acquisitions and collaborations, is to provide researchers with the most comprehensive and highly characterised portfolio of antibodies and antibody products."

The Sigma-Aldrich Foundation includes scientific advancement, education and health and human services among its intentions.

It states that it is dedicated to improving quality of life and aims for researchers all over the world to receive products at attractive costs.

As well as this, it states innovation among its corporate interests and that it wishes to allow talent to reach its maximum potential as well as keeping shareholders and customers.